In the context of melanoma, tumor-associated B cells that activate STAT3 have been shown to enhance tumor progression through the promotion of angiogenesis, implying that STAT3 in B cells could be a potential target for anti-angiogenic therapies [58]. This evidence concerns the gene STAT3 and neoplasm.